Biotech stocks may offer your portfolio an element of growth, and that's because these companies are sharply focused on innovation. They set out to tackle some of the most challenging diseases, and as ...

The market seems to be falling heavily out of love with the AI stocks, and for good reason: CapEx is rising at a staggering ...

Tomorrow BioTech and Green2Gold unite to support biotech and green innovators with labs, mentorship, and a path to ...

The companies Vaxcyte, Generate Biomedicines, and Immunic bagged the biggest biotech funding rounds overall in February 2026.

With fresh billions unlocked in the 2026 U.S. budget and mission‑driven family offices recalibrating after a “nuclear winter, ...

When GSK’s new CEO Luke Miels told investors last month that “smart business development” is a key pillar for his strategy, he wasn’t lying. | Like Merck & Co.’s PAH drug Winrevair—which brought in $1 ...

Investors are increasingly wary of the rare-disease space, spooked by a regulatory shift.

Moderna has agreed to pay Roivant up to $2.25 billion to settle claims that it infringed on Roivant’s patents with its ...

T-cell engager (TCE) specialist Candid Therapeutics has entered into a reverse merger agreement with Rallybio that will allow ...

Jason Kelly, chief executive of Ginkgo Bioworks, spent a surprising amount of time on an earnings call with analysts last ...

X4 Pharmaceuticals is a BUY, driven by a funded Phase 3 trial, current product pipeline, and a strong cash position extending ...